Industry Briefs: May 28, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Bend Research has expanded its existing hot-melt extrusion capacity with the addition of an 18-mm Leistritz twin-screw mixer/extruder. Read More
Bristol-Myers Squibb formed the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. Read More
FEI has launched its Living Lab for structural biology research on the campus of the National Institutes of Health. Read More
Mylan and Sunovion have entered into settlement agreements in the companies’ litigation relating to generic Brovana (arformoterol tartrate) and Xopenex (levalbuterol hydrochloride).
Recipharm secures financing for a EUR 90-million ($112 million) loan facility for further acquisition of niche CDMOs, investment in existing facilities, and building long-term partnerships with major pharmaceuticals companies. Read More
People News
Amgen has announced that Kevin W. Sharer has retired from his post as CEO and the company’s board of directors has appointed Robert A. Bradway his replacement. Read More
DSM has appointed Laura Parks as president and business unit director of finished-dosage business. Read More
Onyx Scientific has appointed Brian Jolly as its European business development director. Read More
Pfizer has named Olivier Brandicourt as president and general manager of its emerging markets and established products business units. Read More
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
